Equity Overview
Price & Market Data
Price: $1.19
Daily Change: -$0.03 / 2.52%
Daily Range: $1.17 - $1.26
Market Cap: $8,722,408
Daily Volume: 71,467
Performance Metrics
1 Week: -8.08%
1 Month: -4.40%
3 Months: -24.84%
6 Months: -5.91%
1 Year: -88.28%
YTD: -86.72%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.